IN2013MU01431A - - Google Patents

Download PDF

Info

Publication number
IN2013MU01431A
IN2013MU01431A IN1431MU2013A IN2013MU01431A IN 2013MU01431 A IN2013MU01431 A IN 2013MU01431A IN 1431MU2013 A IN1431MU2013 A IN 1431MU2013A IN 2013MU01431 A IN2013MU01431 A IN 2013MU01431A
Authority
IN
India
Prior art keywords
abstract
solvents
derived
novel
preparation
Prior art date
Application number
Other languages
English (en)
Inventor
Ravikumar Puppala
Srinivas Laxminarayan Pathi
Dharmaraj Ramachandra Rao
Rajendra Narayanrao Kankan
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd filed Critical Cipla Ltd
Priority to PCT/GB2014/000150 priority Critical patent/WO2014170628A1/en
Priority to CA2909519A priority patent/CA2909519A1/en
Priority to IN1431MU2013 priority patent/IN2013MU01431A/en
Priority to ZA2014/02789A priority patent/ZA201402789B/en
Priority to EP14719344.5A priority patent/EP2986619A1/en
Priority to US14/784,866 priority patent/US10023611B2/en
Publication of IN2013MU01431A publication Critical patent/IN2013MU01431A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN1431MU2013 2013-04-16 2014-04-16 IN2013MU01431A (pm)

Priority Applications (6)

Application Number Priority Date Filing Date Title
PCT/GB2014/000150 WO2014170628A1 (en) 2013-04-16 2014-04-16 Process for the preparation of bortezomib mannitol ester
CA2909519A CA2909519A1 (en) 2013-04-16 2014-04-16 Process for the preparation of bortezomib mannitol ester
IN1431MU2013 IN2013MU01431A (pm) 2013-04-16 2014-04-16
ZA2014/02789A ZA201402789B (en) 2013-04-16 2014-04-16 Process for the preparation of bortezomib mannitol ester
EP14719344.5A EP2986619A1 (en) 2013-04-16 2014-04-16 Process for the preparation of bortezomib mannitol ester
US14/784,866 US10023611B2 (en) 2013-04-16 2014-04-16 Process for the preparation of bortezomib mannitol ester

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1431MU2013 IN2013MU01431A (pm) 2013-04-16 2014-04-16

Publications (1)

Publication Number Publication Date
IN2013MU01431A true IN2013MU01431A (pm) 2015-06-26

Family

ID=50549349

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1431MU2013 IN2013MU01431A (pm) 2013-04-16 2014-04-16

Country Status (6)

Country Link
US (1) US10023611B2 (pm)
EP (1) EP2986619A1 (pm)
CA (1) CA2909519A1 (pm)
IN (1) IN2013MU01431A (pm)
WO (1) WO2014170628A1 (pm)
ZA (1) ZA201402789B (pm)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10023611B2 (en) 2013-04-16 2018-07-17 Cipla Limited Process for the preparation of bortezomib mannitol ester

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE047207T2 (hu) * 2015-04-29 2020-04-28 Nanosilical Devices Srl Bortezomib alapú adagolórendszer
WO2016205790A2 (en) 2015-06-19 2016-12-22 Hanlin Scientific, Inc. Chiral specific boron-containing compounds and their use in treating cancer or amyloidosis
PT109941B (pt) * 2017-03-02 2021-02-09 Hovione Farmaciência, S.A. Conjugados de boro multifuncionais com uma estrutura tripodal, composições farmacêuticas e processos de preparação dos mesmos
US20210393656A1 (en) * 2019-01-11 2021-12-23 Intas Pharmaceuticals Ltd. A process for preparation of a stable pharmaceutical composition of bortezomib

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4499082A (en) 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
US5242904A (en) 1987-06-05 1993-09-07 The Dupont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US5250720A (en) 1987-06-05 1993-10-05 The Dupont Merck Pharmaceutical Company Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
EP0315574A3 (de) 1987-11-05 1990-08-22 Hoechst Aktiengesellschaft Renin-Inhibitoren
US5106948A (en) 1988-05-27 1992-04-21 Mao Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
NZ337364A (en) 1997-02-15 2001-06-29 Millennium Pharm Inc Treatment of infarcts, ischemia and reperfusion through inhibition of NFkappaB
WO1999015183A1 (en) 1997-09-25 1999-04-01 Proscript Inc. PROTEASOME INHIBITORS, UBIQUITIN PATHWAY INHIBITORS OR AGENTS THAT INTERFERE WITH THE ACTIVATION OF NF-λB VIA THE UBIQUITIN PROTEASOME PATHWAY TO TREAT INFLAMMATORY AND AUTOIMMUNE DISEASES
EP1355910B1 (en) 2001-01-25 2011-03-09 The United States of America, represented by the Secretary, Department of Health and Human Services Formulation of boronic acid compounds
DK3385267T3 (da) 2004-03-30 2021-11-01 Millennium Pharm Inc Syntese af boronestere og syreforbindelser
WO2008075376A1 (en) * 2006-12-18 2008-06-26 Natco Pharma Limited Polymorphic forms of bortezomib and process for their preparation
WO2009004350A1 (en) 2007-07-03 2009-01-08 Pliva Hrvatska D.O.O. Methods for preparing bortezomib and intermediates used in its manufacture
JP2010539183A (ja) 2007-09-12 2010-12-16 ドクター・レディーズ・ラボラトリーズ・リミテッド ボルテゾミブおよびその生成のためのプロセス
EP2344165A4 (en) * 2008-10-01 2012-12-05 Reddys Lab Ltd Dr PHARMACEUTICAL COMPOSITIONS COMPRISING BORONIC ACID COMPOUNDS
EP2443129B1 (en) 2009-06-19 2016-11-23 LEK Pharmaceuticals d.d. Process for hydrogenation of halogenoalkenes without dehalogenation
CN102725300B (zh) 2009-12-22 2015-03-11 赛福伦公司 蛋白酶体抑制剂及其制备、纯化、和应用的方法
EP2534159A1 (en) 2010-02-09 2012-12-19 Ranbaxy Laboratories Limited Process for the preparation of bortezomib
ES2548256T3 (es) 2010-10-14 2015-10-15 Synthon Bv Proceso para la preparación de bortezomib y los intermedios para el proceso
MX2015003175A (es) 2012-09-11 2015-07-14 Cipla Ltd Proceso para preparacion de bortezomib.
CA2909519A1 (en) 2013-04-16 2014-10-23 Cipla Limited Process for the preparation of bortezomib mannitol ester

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10023611B2 (en) 2013-04-16 2018-07-17 Cipla Limited Process for the preparation of bortezomib mannitol ester

Also Published As

Publication number Publication date
CA2909519A1 (en) 2014-10-23
WO2014170628A8 (en) 2014-12-18
ZA201402789B (en) 2015-11-25
EP2986619A1 (en) 2016-02-24
US20160075736A1 (en) 2016-03-17
WO2014170628A1 (en) 2014-10-23
US10023611B2 (en) 2018-07-17

Similar Documents

Publication Publication Date Title
PH12018501094A1 (en) Process for the preparation of an apoptosis-inducing agent
MY182428A (en) Crystalline forms of a prolyl hydroxylase inhibitor
IN2014CH00247A (pm)
MX370649B (es) Proceso para la preparacion de teneligliptina.
IN2012MU03723A (pm)
MY194466A (en) Heterophasic polypropylene composition
IN2013MU01431A (pm)
IN2013CH04023A (pm)
MX2015013589A (es) Proceso e intermediario para la preparacion de pregabalina.
IN2013MU03070A (pm)
IN2013MU01111A (pm)
HUP1200695A2 (en) Novel process for preparing travoprost
SI2867231T1 (sl) Primeren postopek za pripravo statinov
IN2013CH05865A (pm)
IN2013MU02813A (pm)
WO2014188334A3 (en) Process for preparation of alogliptin
IN2013MU02699A (pm)
MX2016002186A (es) Proceso para preparar dronedarona y sales de la misma.
IN2012CH02984A (pm)
IN2014CH01391A (pm)
WO2015001565A3 (en) "an improved process for the preparation of 3-aryloxy-3- phenylpropylamine and salt thereof"
MX2015015346A (es) Procedimiento para la preparacion de intermediarios de acido boronico.
IN2013MU02748A (pm)
EP2989097A4 (en) Improved processes for the preparation of linezolid using novel intermediates
IN2013MU03769A (pm)